Drug
Danuglipron clinical trials
Also written PF-06882961.
- studies test it
- 18
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
18 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 6 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 0
Often tested with
Tested in the same studies.
Midazolam (2) · Atorvastatin (1) · Rosuvastatin (1) · Ervogastat (1) · PF-07976016 (1)
Studies
Open first, then newest update. How each study uses danuglipron is read from its arms, and is right about nine times in ten.
Testing it · 18
- Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or ObesityTerminatedPhase 1PfizerNCT06910839Written as PF-06882961
- A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or ObesityCompletedPhase 1PfizerNCT06568731Written as Danuglipron
- A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With ObesityCompletedPhase 2PfizerNCT04707313Written as PF-06882961 (Cohorts 1 and 2)
- Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy AdultsCompletedPhase 1PfizerNCT06153758Written as Danuglipron
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes MellitusCompletedPhase 1PfizerNCT04889157Written as PF-06882961
- STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTSCompletedPhase 1PfizerNCT05093205Written as PF-06882961
- STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENTCompletedPhase 1PfizerNCT04616027Written as PF-06882961 20 mg
- STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENTCompletedPhase 1PfizerNCT04604496Written as PF-06882961 20MG
- Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With ObesityCompletedPhase 1PfizerNCT04621227Written as PF-06882961
- A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise HealthyCompletedPhase 1PfizerNCT04839393Written as PF-06882961 + PF-06865571
- A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITYCompletedPhase 2PfizerNCT04617275Written as PF-06882961
- A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes MellitusCompletedPhase 2PfizerNCT03985293Written as PF-06882961
- STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITYCompletedPhase 1PfizerNCT04616339Written as PF-06882961 100 mg
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes MellitusCompletedPhase 1PfizerNCT04552470Written as PF-06882961
- Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961CompletedPhase 1PfizerNCT04495140Written as [14C]PF-06882961, 50 mg
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 DiabetesCompletedPhase 1PfizerNCT03538743Written as PF-06882961
- A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961CompletedPhase 1PfizerNCT03492697Written as PF-06882961 Immediate Release Tablet
- First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult SubjectsCompletedPhase 1PfizerNCT03309241Written as PF-06882961
Given in every arm · 2 — danuglipron is usual care beside what is tested
- A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or ObeseCompletedPhase 1PfizerNCT06567327Written as Danuglipron
- A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.CompletedPhase 1PfizerNCT06541678Written as Danuglipron
Codes
What other systems call danuglipron · ClinicalTrials.gg INT002098
- MeSH (NLM) C000731016danuglipronConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DN9IUI24GPDANUGLIPRONConfirmed FDA, NLM, Wikidata
- Wikidata Q63141738danuglipronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C177080DanuglipronOne source FDA
- DrugBank DB16043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731016 | danuglipron | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DN9IUI24GP | DANUGLIPRON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q63141738 | danuglipron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C177080 | Danuglipron | One source FDA |
| DrugBank | DB16043 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.